Cortical hyperostosis following long-term administration of prostaglandin E1 in infants with cyanotic congenital heart disease.

No abstract is available for this paper.

• Publication year

  1980

• Venue

  Jornal de Pediatria

• Publication date

  1980-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S0022-3476(80)80282-4PMID 7000997
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Long-term low-dose prostaglandin E1 administration.

  1980cited by this paper
• Oral prostaglandin E2 in pulmonary atresia.

  1979cited by this paper
• Prolonged prostaglandin E1 infusion in an infant with cyanotic congenital heart disease.

  1978cited by this paper
• Prostaglandin and damage to ductus arteriosus.

  1977cited by this paper
• E‐Type Prostaglandins: A New Emergency Therapy for Certain Cyanotic Congenital Heart Malformations

  1976cited by this paper
• Formalin infiltration of the ductus arteriosus. A method for palliation of infants with selected congenital cardiac lesions.

  1975cited by this paper
• Medical manipulation of the ductus arteriosus.

  1975cited by this paper
• DRUGS IN HOSPITAL.

  1965cited by this paper
• Infantile cortical hyperostoses.

  1946cited by this paper

• COX‐2 in Fracture Callus Chondro‐Osseous Junction Osteoclasts Regulates Chondrocyte Hypertrophy and Callus Vasculogenesis

  2025cites this paper
• Adverse Drug Reactions in Children with Congenital Heart Disease: A Scoping Review

  2024influential citation
• Caffey disease is associated with distinct arginine to cysteine substitutions in the proα1(I) chain of type I procollagen

  2021cites this paper
• KMN-159, a novel EP4 receptor selective agonist, stimulates osteoblastic differentiation in cultured whole rat bone marrow.

  2020cites this paper
• Prostaglandins and bone metabolism

  2020cites this paper
• Role and Regulation of Mechanotransductive HIF-1α Stabilisation in Periodontal Ligament Fibroblasts

  2020cites this paper
• Radiographic overlap of recurrent Caffey disease and chronic recurrent multifocal osteomyelitis (CRMO) with considerations of molecular origins

  2019cites this paper
• Prostaglandins and Bone.

  2019cites this paper
• Crispr-Cas9 engineered osteogenesis imperfecta type V leads to severe skeletal deformities and perinatal lethality in mice.

  2018cites this paper
• Prolonged prostaglandin-E2-associated periosteal reaction and elevated C-reactive protein levels

  2017cites this paper
• [Infantile cortical hyperostosis: Case report].

  2016cites this paper
• A Case of Localized Neuroblastoma in Caffey Disease, with Early and Uncommon Progression

  2015cites this paper
• Effects of prostaglandin E1 on callus formation in rabbits

  2015cites this paper
• Regulation of prostaglandin EP1 and EP4 receptor signaling by carrier-mediated ligand reuptake

  2014cites this paper
• Caffey disease: new perspectives on old questions.

  2014cites this paper
• Fracture healing and lipid mediators.

  2014cites this paper
• Immunohistochemical Localization of Key Arachidonic Acid Metabolism Enzymes during Fracture Healing in Mice

  2014cites this paper
• Two Japanese familial cases of Caffey disease with and without the common COL1A1 mutation and normal bone density, and review of the literature

  2014cites this paper
• the enthesis NSAID therapy effects on healing of bone, tendon, and

  2013cites this paper
• NSAID therapy effects on healing of bone, tendon, and the enthesis.

  2013cites this paper
• Bone and Joints

  2013cites this paper
• Hiperostosis asociada a prostaglandinas. Reporte de tres casos Hyperostosis associated with prostaglandins. Report of three cases

  2013cites this paper
• Arachidonic Acid: A Bridge between Traumatic Brain Injury and Fracture Healing

  2012cites this paper
• Elevation of Prostaglandin E2 in Lung Cancer Patients with Digital Clubbing

  2012cites this paper
• Prostaglandin transporter mutations cause pachydermoperiostosis with myelofibrosis

  2012cites this paper
• [Neonatal cortical hyperostosis. A side effect of prolonged prostaglandin E1 infusion].

  2011cites this paper
• Primary hypertrophic osteoarthropathy with digital clubbing and palmoplantar hyperhidrosis caused by 15‐PGHD/HPGD loss‐of‐function mutations

  2011cites this paper
• Anabolic Agents and Bone Quality

  2011cites this paper
• Physiologically based mathematical model of transduction of mechanobiological signals by osteocytes

  2011cites this paper
• The effect of risedronate on osteogenic lineage is mediated by cyclooxygenase-2 gene upregulation

  2010cites this paper
• Growth Factors and Signalling Molecules for Cartilage Tissue Engineering – from Embryology to Innovative Release Strategies for Guided Tissue Engineering

  2010cites this paper
• PEDIATRIC CARDIOLOGY Morphologic Features of the Ductus Arteriosus After Prostaglandin E 1 Administration for Ductus- Dependent Congenital Heart Defects

  2010cites this paper
• Basal bone phenotype and increased anabolic responses to intermittent parathyroid hormone in healthy male COX-2 knockout mice.

  2010cites this paper
• Imprägnierung von β-TCP Keramiken mit biomimetischen Substanzen zur Beschleunigung der Knochenbildung in einer experimentellen Studie in Schafen

  2009cites this paper
• Chapter 15 – Imaging Findings of Drug-Related Musculoskeletal Disorders

  2009cites this paper
• Ecology of wound healing in the oral cavity.

  2009cites this paper
• Periostitis Secondary to Prolonged Voriconazole Therapy in Lung Transplant Recipients

  2009cites this paper
• Hyperostose corticale infantile

  2009cites this paper
• Perspectives for the tissue engineering of cartilage from a biological and biomaterial point of view.

  2008cites this paper
• Continuous PGE 2 leads to net bone loss while intermittent PGE 2 leads to net bone gain in lumbar vertebral bodies of adult female rats

  2008cites this paper
• Effects of prostaglandin E1 application on rat incisal sockets.

  2008cites this paper
• A Comprehensive Clinicopathologic Analysis Suggests that Vascular Endothelial Growth Factor (VEGF) is the Most Likely Mediator of Periosteal New Bone Formation (PNBF) Associated with Diverse Etiologies

  2008cites this paper
• 68 – Therapeutic Opportunities for Bone Grafting

  2008cites this paper
• Mutations in 15-hydroxyprostaglandin dehydrogenase cause primary hypertrophic osteoarthropathy

  2008cites this paper
• Infections in Bone

  2008cites this paper
• Drug-Related Bone and Soft Tissue Disorders

  2008cites this paper
• Effects of Iloprost on Calvarial Sutures

  2008cites this paper
• Continuous PGE2 leads to net bone loss while intermittent PGE2 leads to net bone gain in lumbar vertebral bodies of adult female rats.

  2008cites this paper
• Prostaglandine im Knochen- und Knorpelmetabolismus

  2008cites this paper
• The effects of prostaglandin E2 in growing rats: Increased metaphyseal hard tissue and cortico-endosteal bone formation

  2007cites this paper
• Eicosanoic fatty acid reduction in the tibiotarsus of biotin-deficient chicks

  2007cites this paper
• Expanding the phenotypic spectrum of Caffey disease

  2007cites this paper
• Strontium Ranelate Promotes Osteoblastic Differentiation and Mineralization of Murine Bone Marrow Stromal Cells: Involvement of Prostaglandins

  2007cites this paper
• Successful Treatment of Chronic Recurrent Multifocal Osteomyelitis With Indomethacin: A Preliminary Report of Five Cases

  2007cites this paper
• Cortical hyperostosis secondary to prostaglandin E1 therapy.

  2007cites this paper
• Perspectives for the Tissue Engineering of Cartilage from a Biological and Biomaterial Point of View

  2007cites this paper
• Continuous infusion of PGE2 is catabolic with a negative bone balance on both cancellous and cortical bone in rats.

  2007cites this paper
• Cyclooxygenase-2 gene disruption promotes proliferation of murine calvarial osteoblasts in vitro.

  2007cites this paper
• The roles of cyclooxygenase-2 and prostaglandin E2 in periodontal disease.

  2007cites this paper
• Identification of a key regulatory pathway in bone regeneration using a novel mouse fracture model

  2007cites this paper
• Pseudo-widening of cranial sutures as a feature of long-term prostaglandin E1 therapy

  2006cites this paper
• Selective prostaglandin agonists as anabolic agents

  2006cites this paper
• Effect of misoprostol on bone mineral density in women with postmenopausal osteoporosis.

  2006cites this paper
• Soft-tissue swelling in two neonates during prostaglandin E1 therapy

  2006cites this paper
• Literature in pediatric radiology

  2006influential citation
• Reversibility of cortical hyperostosis following long-term prostaglandin E1 therapy in infants with ductus-dependent congenital heart disease

  2006cites this paper
• Anabolic effect of prostaglandins

  2006cites this paper
• Cyclooxygenases and prostaglandin E2 receptors in growth plate chondrocytes in vitro and in situ – prostaglandin E2 dependent proliferation of growth plate chondrocytes

  2006cites this paper
• Radiologic features of gastric outlet obstruction in infants after long-term prostaglandin administration

  2005cites this paper
• The effect of nonsteroidal anti-inflammatory agents on spinal fusion.

  2005cites this paper
• The increase in spinal bone density that occurs in response to fluoride therapy for osteoporosis is not maintained after the therapy is discontinued

  2005cites this paper
• Prostaglandins: Mechanisms of action and regulation of production in bone

  2005cites this paper
• Drug-induced bone disorders

  2005cites this paper
• Plain film and CT observations in prostaglandin-induced bone changes

  2005cites this paper
• Case report 701

  2005cites this paper
• Bone-targeting macromolecular therapeutics.

  2005cites this paper
• Caffey disease: an unlikely collagenopathy.

  2005cites this paper
• Salicylic acid-derived poly(anhydride-esters) inhibit bone resorption and formation in vivo.

  2005cites this paper
• A selective EP4 receptor antagonist abrogates the stimulation of osteoblast recruitment from bone marrow stromal cells by prostaglandin E2 in vivo and in vitro.

  2004cites this paper
• Increased bone growth by local prostaglandin E2 in rats

  2004cites this paper
• Bone within a bone.

  2004cites this paper
• Effects of long-term daily administration of prostaglandin-E2 on maintaining elevated proximal tibial metaphyseal cancellous bone mass in male rats

  2004cites this paper
• Possible involvement of p38 MAP kinase in prostaglandin E1-induced ALP activity in osteoblast-like cells.

  2004cites this paper
• Role of EP3 and EP4 prostaglandin receptors in reorganization of the cytoskeleton in mature human osteoclasts.

  2004cites this paper
• Osteoid osteoma simulating an osteocartilaginous exostosis

  2004cites this paper
• Production of new trabecular bone in osteopenic ovariectomized rats by prostaglandin E2

  2004cites this paper
• Aneurysmal change of the ductus arteriosus after prostaglandin E1 administration for pulmonary atresia: Demonstration with magnetic resonance imaging

  2004cites this paper
• Patent developments in anabolic agents for treatment of bone diseases

  2003cites this paper
• Prostaglandin E--a powerful anabolic agent for generalized or site-specific bone formation.

  2003cites this paper
• The Mechanisms of the Inhibitory Effects of Nonsteroidal Anti‐Inflammatory Drugs on Bone Healing: A Concise Review

  2003cites this paper
• Defect repair in the rat mandible with bone morphogenic protein 5 and prostaglandin E1.

  2003cites this paper
• Novel therapeutic targets in osteoporosis

  2002cites this paper
• The design and synthesis of selective prostaglandin analogs as bone anabolic agents for the potential treatment of osteoporosis.

  2002cites this paper
• Drug-Induced Metabolic Bone Disorders

  2002cites this paper
• Gastric thumbprinting: diffuse gastric wall mucosal and submucosal thickening in infants with ductal-dependent cyanotic congenital heart disease maintained on long-term prostaglandin therapy

  2002cites this paper
• Hypertrophic osteoarthropathy caused by PGE1 in a patient with congestive heart failure during cardiac rehabilitation.

  2002cites this paper
• Stimulation of CFU-f formation by prostaglandin E2 is mediated in part by its degradation product, prostaglandin A2.

  2001cites this paper
• Expression of the prostaglandin E(2) (PGE(2)) receptor subtype EP(4) and its regulation by PGE(2) in osteoblastic cell lines and adult rat bone tissue.

  2001cites this paper
• Effect of administration of lipoprostaglandin E1 on physical activity and bone resorption in patients with neurogenic intermittent claudication

  2001cites this paper
• Systemic prostaglandin E2 increases cancellous bone formation and mass in aging rats and stimulates their bone marrow osteogenic capacity in vivo and in vitro.

  2001cites this paper